The first clinically approved aminopeptidase inhibitor, named bestatin, was thought of as an immunomodulating drug; however, later on, it has been demonstrated that bestatin also exhibited antiproliferative effects in several cancer cell lines, including leukemic cells, highlighting its activity as an anticancer drug [104]. Here, CPQ is linked to cancer.